ADCs and Other Novel Agents Boost HER2+ Breast Cancer Paradigm
Published: Thursday, Apr 09, 2020
Chau T. Dang, MD
Several FDA approvals over the past year have propelled progress in HER2-positive breast cancer, and other novel agents are rapidly advancing through the pipeline, explained Chau T. Dang, MD.
... to read the full story